Because activation of FXR is a defined target in treating metabolic syndrome and specific ligands for this receptor are tested in NASH patients [66] our data suggest, that similarly to PPARγ, activation of FXR might contribute to the beneficial effects observed under VSL#3 intervention. This evidence concerns the gene PPARG and metabolic dysfunction-associated steatohepatitis.